Clinical trials: COVID-19 Vaccination
COVID-19, Vaccine Hesitancy
Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia
The purpose of this community-engaged study is to test the ability of county-level strategies to increase uptake of COVID-19 vaccination.
- Trial name
- K-VAC (NCT06505993)
- Testing
- Health Communication, Health Communication + Structural
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Marc Kiviniemi
Covid19, Vaccine Refusal
COVID-19 Vaccine Education at the Point of Testing to Increase Vaccine Uptake in Vulnerable Communities in SE Louisiana
This project is a 2-year study to investigate vaccine hesitancy and vaccine completion among vulnerable communities in the Southeastern Louisiana region.
- Conditions
- Covid19, Vaccine Refusal, Vaccine Hesitancy
- Trial name
- NCT04939506
- Testing
- COVID-19 Vaccine Education at the Point of COVID-19 Testing
- Where
- United States
- Volunteers
- 377 people, healthy volunteers welcome
- Sponsor
- Xavier University of Louisiana.
Immunization Against COVID-19
Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2
The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Ergoferon as a non-specific preventive medicine for COVID-19 in…
- Trial name
- NCT05069649
- Testing
- Ergoferon
- Where
- 33 sites in Russia
- Volunteers
- 1,057 people
- Sponsor
- Materia Medica Holding
COVID-19, Solid Tumor
National Project on Vaccines, COVID-19 and Frail Patients
This is a multicentre observational study with the aim of evaluating the antibody and cellular response after vaccination for SARS-CoV-2 with Pfizer-BioNTech or Moderna vaccines in frail subjects with impaired immuno-competence…
- Conditions
- COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder
- Trial name
- VAX4FRAIL (NCT04848493)
- Testing
- COVID-19 vaccines
- Where
- 12 sites in Italy
- Volunteers
- 747 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Covid19
COVID-19 Vaccinations With a Sweepstakes
To reach herd immunity for COVID-19, experts estimate that 70% of the population will need to be vaccinated. However, vaccination rates have begun to slow down in the United States.
- Trial name
- NCT04951310
- Testing
- Philly Vax Sweepstakes
- Where
- United States
- Volunteers
- 3,827,656 people
- Sponsor
- University of Pennsylvania
Coronavirus, Coronavirus Infection
BCG Vaccine for Health Care Workers as Defense Against COVID 19
SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW).
- Conditions
- Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere
- Trial name
- BADAS (NCT04348370)
- Testing
- BCG Vaccine
- Where
- 6 sites in United States
- Volunteers
- 659 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Ebola Virus Disease, COVID-19
Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses
Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases.
- Trial name
- NCT06587503
- Testing
- BioNTech - Pfizer COVID-19 vaccine, 1mL saline solution, rVSV∆G-ZEBOV-GP
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
Multiple Sclerosis, Covid19
Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis
This observational study is intended to evaluate the effect of disease modifying therapies on antibody responses to the mRNA-1273 vaccine (Moderna) for COVID-19.
- Trial name
- NCT04834401
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- St. Barnabas Medical Center
Covid19, Vaccine Refusal
VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans
This is a prospective, randomized controlled trial that will evaluate the effectiveness of two different targeted outreach interventions aimed at increasing Covid-19 vaccine uptake.
- Trial name
- VEText (NCT04805931)
- Testing
- Behavioral economics
- Where
- United States
- Volunteers
- 4,311 people, healthy volunteers welcome
- Sponsor
- VA Puget Sound Health Care System
Vaccination Refusal
Effectiveness of a Mayan Language Social Media Campaign on COVID-19 Vaccine Beliefs in Guatemala
Prior evidence, including formative work supporting the development of this study, suggests there is widespread vaccine hesitancy among Indigenous communities in Guatemala, fueled by mistrust in the health system, lack of…
- Trial name
- NCT05252936
- Testing
- COVID-19 vaccine social media campaign exposure
- Where
- Guatemala
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Stanford University
Covid19
Evolution of Protective Immunization Against COVID-19 Among Hospital Workers in Health Care Facilities
To measure the immunization rate (seroneutralization) in a population of exposed hospital workers (nursing staff assigned to dedicated COVID-19 care units, laboratory staff handling COVID-19 samples).
- Trial name
- ICONE (NCT05011344)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2
Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers
This is a multicentre, open-label Phase 1/2 study, with a first-in-human (FIH) dose escalation part (Phase 1 study) followed by an open-label single arm (or two-arms, randomized) dose expansion part (Phase 2 study).
- Conditions
- COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2, COVID-19 Immunisation
- Trial name
- NCT04788459
- Testing
- COVID-eVax, Cliniporator® and EPSGun
- Where
- 4 sites in Italy
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Takis
Hospital Staff, Vaccined Againt COVID-19
Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff
Vaccination against COVID-19 is a major public health issue to control the epidemic and reduce the number of severe infections and deaths.
- Trial name
- COVIDIM (NCT04896788)
- Testing
- Monitoring of the immune response
- Where
- France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
COVID-19
Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine
This is a randomized, open-label, parallel-controlled study to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) after…
- Trial name
- NCT05043259
- Testing
- inactive SARS-CoV-2 vaccine (Vero cell), Low dose aerosolized Ad5-nCoV, High dose aerosolized Ad5-nCoV
- Where
- China
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose…
- Trial name
- MOSAIC (NCT04894435)
- Testing
- mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant]
- Where
- 8 sites in Canada
- Volunteers
- 669 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
COVID-19
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
This is a randomized, double-blind, active-controlled Phase Ⅲ clinical trial, as well as an immuno-bridging clinical trial by parallel testing previous serum after primary immunization of COVID-19 vaccine (Vero cell), inactivated…
- Trial name
- NCT05381350
- Testing
- COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant), COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)
- Where
- China
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
HIV Infections
Immunogenicity of COVID-19 Vaccination in PLWH
Various facts support the study of COVID-19 vaccine immunogenicity in People Living With HIV (PLWH) at this time: (1) Many PLWH in Canada will be eligible to receive COVID-19 vaccination as they are in a high priority risk group…
- Trial name
- HIV-COV (NCT04894448)
- Testing
- COVID-19 Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 500 people
- Sponsor
- CIHR Canadian HIV Trials Network
COVID-19
Immune Responses to COVID-19 Infection or Vaccination
The overall purpose of this observational cohort study is to characterize COVID-specific immune responses to SARS-CoV-2 exposure or COVID vaccination in a real-world setting.
- Trial name
- NCT05379478
- Testing
- Laboratory assessment of antibody profiles
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Aditxt, Inc.
Systemic Sclerosis, SARS-CoV 2 Vaccination
Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation
On December 27th 2020, the implementation of SARS-CoV-2 vaccination in France first became available amongst all immunosuppressed patients at very high risk of severe Coronavirus Disease (COVID-19) infection, specifically for…
- Trial name
- COV2-VACCinSSc (NCT05960058)
- Volunteers
- 72 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19
Using Text Messages to Improve COVID-19 Vaccination Uptake
COVID-19 vaccinations significantly reduce the risk of getting seriously ill or dying from COVID-19. Since December 2020, the UK has rolled out vaccinations according to the Joint Committee for Vaccinations and Immunity (JCVI)…
- Trial name
- NCT04895683
- Testing
- Text message content
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust